Background {#Sec1}
==========

Aortic stenosis (AS) is the most frequent degenerative valvular heart disease in Western countries with a prevalence that has increased in parallel with the aging demographic of the population \[[@CR1], [@CR2]\]. AS patients are typically elderly with multiple co-morbidities, which precludes traditional surgical aortic valve replacement (SAVR) \[[@CR3], [@CR4]\]. Transcatheter aortic valve replacement (TAVR) has emerged over the last decade as an innovative procedure to deliver aortic valves percutaneously in a minimally invasive manner; based on landmark studies, guidelines now recommend TAVR as the preferred treatment for severe AS patients who are inoperable, and as a reasonable alternative in patients with high operative risk \[[@CR5]\]. Emerging evidence supports the expansion of TAVR indications to intermediate risk patients \[[@CR6]\]. As such, there has been an exponential growth in the demand for TAVR which will likely increase in the future.

Given the extensive pre-procedural diagnostic work-up, the complexity of the prosthesis and procedure, and the requirement for close post-procedural follow-up, TAVR is extremely resource intensive \[[@CR7]--[@CR9]\]. Given the current economic environment, there is increasing need to improve the efficiency of health care delivery in complex interventions such as TAVR, in order to improve the overall value of health care and also improve equitable access to this life-saving intervention within strict budgetary constraints. One such area specific to TAVR is improving post-procedural length of stay (LOS). In addition to its economic benefits, optimizing LOS in an elderly population has a number of other potential clinical advantages such as reducing infection rates, increasing rehabilitation rates, avoiding malnutrition, and improving overall psychological status.

Although TAVR has been shown to have shorter hospitalizations compared to SAVR \[[@CR10]\], some TAVR patients nonetheless have prolonged post-procedural stay \[[@CR7], [@CR11]\]. Moreover, there is a wide variation in reports of TAVR LOS reinforcing the likelihood of inefficient care. For example, some studies report the mean hospital stay following TAVR to be 11--13 days \[[@CR7], [@CR12]\], while other contemporary cohorts demonstrate hospitalization duration shorter than three days in approximately 30% of patients \[[@CR11], [@CR13], [@CR14]\].

There is a paucity of data on the drivers that impact LOS post-TAVR. Elucidating these factors is important so as to identify potentially modifiable factors that can lead to quality improvement interventions to optimize LOS. To address this gap in knowledge, we sought to identify the major drivers of post-TAVR LOS using a contemporary multinational registry.

Methods {#Sec2}
=======

We conducted a retrospective cohort study, with patients recruited from three tertiary institutions, including two in Toronto, Canada (Sites 1 and 3) and one in Tel Aviv, Israel (Site 2). Research ethics board approval was obtained from all centers for the prospective databases. The need for individual patient consent was waived by all the institutional review boards.

Patient selection {#Sec3}
-----------------

Patients were identified from the TAVR registries from each institution. Each registry collects data on all TAVR patients prospectively. Inclusion criteria were all patients that had a TAVR procedure from January 1st, 2012 to December 31st, 2014. This time frame was chosen in order to include only patients receiving a contemporary TAVR valve procedure, and after each site completed at least 100 cases to overcome the learning curve associated with TAVR. We treated in-hospital death as a competing risk and included patients who died during the procedure or during the TAVR hospitalization.

Outcome variable {#Sec4}
----------------

The primary outcome was the LOS post-TAVR procedure. The day of the TAVR was considered time 0, with each 24-h period after this recorded as 1 day. Additional outcomes of interest included peri-procedural minor and major complications, which were defined according to the Valve Academic Research Consortium (VARC- 2) criteria \[[@CR15]\].

Covariates {#Sec5}
----------

We also documented the length of time (in days) patients were admitted prior to the TAVR procedure as well as the total LOS, from the date of admission to discharge from the TAVR hospital. For the purpose of analyses, we categorized pre-TAVR admission into 2 groups: a) those admitted electively up to two days prior to the procedure and b) those with a TAVR pre-admission of ≥3 days. This categorization was consistent with these hospitals' clinical practice based on the advice of our clinical experts, as patients admitted ≥3 days pre-TAVR have pre-procedural clinical deterioration. We determined if the procedure was done 1 day prior to the weekend and contrasted these from procedures done earlier in the week. Patient characteristics that were abstracted from the registries included age, gender, body-mass index (BMI), co-morbidities, as well as mean gradient across the aortic valve.

Peri-procedural risk of in-hospital/30 day mortality was captured by the Society for Thoracic Surgery (STS) score \[[@CR16], [@CR17]\]. This score includes approximately 30 variables, including demographics, risk factors, previous interventions, pre-operative status, hemodynamics, and coronary anatomy, and has been well validated to accurately predict peri-operative mortality and morbidity.

Procedural factors included the access type, trans-catheter heart valve type, conscious or general anesthesia, and procedural time. We also included the year of the procedure to account for temporal improvements in care delivery.

Statistical analysis {#Sec6}
--------------------

Data completeness was verified for all covariates and there were \<1% missing data in any co-morbidity field with the exception of EuroScore \[[@CR18]\]; as such a complete case analysis was conducted. Descriptive statistics were compared across the 3 hospitals for baseline data, procedure characteristics, and complications, with χ^2^ tests for categorical variables and one-way analysis of variance (ANOVA) for continuous variables.

In order to identify the drivers of LOS, we developed a cause-specific Cox-proportional hazard model, where the dependent variable was the post-TAVR LOS, measured in days \[[@CR19], [@CR20]\]. In our study, this is analogous to modeling the rate (or hazard) of being discharged. Hazard ratios (HR) greater than 1 indicate a shorter LOS, while HRs less than 1 indicate a longer LOS. We built a cause-specific Cox model to account for the competing risk of in-hospital death, which precludes the possibility of the primary outcome (discharge). The models included a sandwich type variance estimator to account for clustering of patients at each of the three institutions. We compared the unadjusted LOS between the 3 hospitals using this model.

Prior to inclusion into the final covariate-adjusted model, we assessed all baseline factors for co-linearity based on the variance inflation factor but found no important multi-colinearities. To build the final covariate adjusted model, we planned to include all variables except for EuroScore due to \>5% missing data. The results for creatinine lacked face validity in the adjusted model so it was excluded. All other variables were included as this was an explanatory model. The proportional hazards assumption was tested by computing Martingale residuals for the final model.

A sensitivity analysis was conducted to understand the role of complications in TAVR post-procedural LOS. For each complication, we calculated both an unadjusted HR and one adjusted for all co-variates in the full model. All of the analyses were considered significant at a two-tailed *p*-value of less than 0.05. All analysis was done with SAS 9.3.

Results {#Sec7}
=======

We included a total of 809 patients from three centers over the time period of interest. Mean pre-TAVR LOS differed between the three sites. Site two routinely admitted elective patients one to two days before TAVR, while the other sites generally admitted these patients on the morning of the procedure (Table [1](#Tab1){ref-type="table"}). Figure [1](#Fig1){ref-type="fig"} demonstrates the post-TAVR LOS. Approximately 27.1% of patients had post-procedural LOS between 2 to 3 days. The three sites show no significant differences in terms of post-TAVR or total LOS. The mean post-procedural LOS was 6.6 days, with means of 6.9, 5.8 and 7.7 at the three sites, while mean total LOS was calculated at 8.8 days across sites, with site-specific values of 9.8, 7.9 and 9.4, respectively.Table 1Baseline Patient and Procedural Characteristics. Cohort baseline and procedural characteristics according to site. All covariates are presented as frequencies and percentages, with the exception of mean values. Mean values include standard deviationTotal (*N* = 809)Site 1 (*n* = 164)Site 2 (*n* = 406)Site 3 (*n* = 239)*p* ValuePatient Characteristics Age (years)82.7 ± 6.483.7 ± 6.482.4 ± 6.282.6 ± 6.70.095 Female415 (51.3%)79 (48.2%)219 (53.9%)117 (49.0%)0.316 BMI27.1 ± 5.327.0 ± 6.127.3 ± 5.326.6 ± 4.60.224 STS6.0 ± 5.44.4 ± 2.84.3 ± 2.910.0 ± 7.6\<0.001 NYHA\<0.001  12 (0.3%)2 (1.2%)00  299 (12.3%)15 (9.2%)55 (13.6%)29 (12.3%)  3505 (62.9%)120 (73.6%)227 (56.2%)158 (67.0%)  4197 (24.5%)26 (16.0%)122 (30.2%)49 (20.8%) Atrial Fibrillation280 (34.6%)68 (41.5%)135 (33.3%)77 (32.2%)0.114 Hypertension717 (88.6%)141 (86.0%)358 (88.2%)218 (91.2%)0.245 Diabetes Mellitus279 (34.5%)48 (29.3%)155 (38.2%)76 (31.8%)0.075 Dyslipidemia645 (79.8%)114 (69.5%)333 (82.2%)198 (82.9%)0.001 COPD129 (16.0%)16 (9.8%)55 (13.6%)58 (24.3%)\<0.001 Coronary Artery Disease520 (64.3%)87 (53.1%)260 (64.0%)173 (72.4%)\<0.001 Peripheral Vascular Disease93 (11.5%)24 (14.6%)17 (4.2%)52 (21.8%)\<0.001 Dialysis26 (3.2%)5 (3.1%)10 (2.5%)11 (4.6%)0.328 Permanent Pacemaker101 (12.5%)25 (15.2%)55 (13.6%)21 (8.8%)0.103 Prior Stroke120 (14.8%)35 (21.3%)52 (12.8%)33 (13.8%)0.030 Prior Cardiac Surgery203 (25.1%)46 (28.1%)89 (21.9%)68 (28.5%)0.113 Prior PCI196 (24.2%)32 (19.5%)55 (13.6%)109 (45.6%)\<0.001 Pre-Procedural Ejection Fraction (%)54.3 ± 10.751.7 ± 9.055.1 ± 8.654.5 ± 14.30.003 Pre-Procedural Mean Pressure Gradient (mmHg)46.4 ± 15.948.8 ± 16.346.2 ± 15.045.2 ± 16.80.071 Pre-Procedural Creatinine (μmol/L)107.9 ± 64.0113.6 ± 88.9104.0 ± 58.9110.6 ± 50.50.203Procedural Characteristics Procedure Year0.015  2012224 (27.7%)42 (25.6%)129 (31.8%)53 (22.2%)  2013274 (33.9%)66 (40.2%)131 (32.3%)77 (32.2%)  2014311 (38.4%)56 (34.2%)146 (36.0%)109 (45.6%) Procedure Prior to Weekend^a^185 (22.9%)2 (1.2%)26 (6.4%)157 (65.7%)\<0.001 Procedure Time (min)161.1 ± 67.587.4 ± 38.8168.9 ± 50.1199.6 ± 69.7\<0.001 Access Site\<0.001  Transfemoral737 (91.1%)111 (67.7%)405 (99.8%)221 (92.5%)  Subclavian2 (0.3%)01 (0.3%)1 (0.4%)  Suprasternal1 (0.1%)1 (0.6%)00  Direct Aortic26 (3.2%)10 (6.1%)016 (6.7%)  Transapical43 (5.3%)42 (25.6%)01 (0.4%) Anesthesia Type\<0.001  General Anesthesia408 (50.4%)164 (100%)5 (1.2%)239 (100%)  Local/Conscious Sedation401 (49.6%)0401 (98.8%)0 Valve Used\<0.001  Medtronic CoreValve or Evolut R458 (56.7%)1 (0.6%)253 (62.6%)204 (85.3%)  Edwards XT or S3332 (41.2%)155 (94.5%)146 (36.1%)31 (13%)  Portico17 (0.2%)8 (4.9%)5 (1.2%)4 (1.7%) Valve in Valve34 (4.2%)8 (4.9%)026 (10.9%)\<0.001 Pre-TAVR Admission\<0.001  0 days305 (37.7%)115 (70.12%)1 (0.3%)189 (79.1%)  1--2 days415 (51.3%)14 (8.54%)382 (94.1%)19 (8%)   ≥ 3 days89 (11%)35 (21.34%)23 (5.7%)31 (13%)*BMI* Body Mass Index, *COPD* Chronic Obstructive Pulmonary Disease, *NYHA* New York Heart Association functional classification, *PCI* percutaneous coronary intervention, *STS* Society of Thoracic Surgeons adult cardiac surgery risk score^a^Refers to procedures that take place one day prior to the weekend Fig. 1Distribution of Post-TAVR Length of Stay of Discharged Patients. Figure shows percentage of patients discharged in each time period following TAVR. All patients have a minimum LOS of 2 days

The incidence of complications for the entire cohort is summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S1, as is post-procedure aortic regurgitation and post-procedure mitral regurgitation. Thirty patients (3.7%) died in hospital, while 30-day mortality was 4.9%. The rates of complications were comparable to those found in the literature, with 18 (2.2%) having a stroke, 107 (13.2%) requiring a permanent pacemaker, 49 (6.1%) suffering from a major vascular complication, and 37 (4.6%) having major bleeding.

As seen in Table [2](#Tab2){ref-type="table"}, there was a temporal effect on LOS identified in the multivariable models, with patients undergoing TAVR in 2012 having a longer LOS compared to those in 2014. We found the following patient characteristics to be associated with longer length of stay: prior atrial fibrillation (HR = 0.76, 95% CI 0.69--0.84, *p* \< 0.001), each one-year increase in patient age (HR = 0.990, 95% CI 0.985--0.995, *p* \< 0.001), and patient urgency as indicated by pre-TAVR admission of three or more days (HR = 0.64, 95% CI 0.46--0.90, *p* = 0.009).Table 2Relationship between Baseline and Procedural Characteristics with Post-TAVR Length of Stay, Adjusted by Model Covariates. Multivariable analysis of the variables associated with length of stayParameterHazard Ratio (95% Confidence Interval)*p* ValueYear 2014Referent 20120.78 (0.68--0.9)\<0.001 20130.85 (0.73--0.98)0.021Sex FemaleReferent Male1.12 (0.97--1.3)0.133Age0.99 (0.99--1)\<0.001Pre-TAVR Admission 0--2 daysReferent  ≥ 3 days0.64 (0.46--0.9)0.009BMI1 (0.98--1.02)0.920STS Risk Score0.98 (0.96--1)0.064NYHA Class 4Referent 1--21.28 (1.1--1.49)0.001 31.16 (1.03--1.31)0.019Atrial Fibrillation0.76 (0.69--0.84)\<0.001Hypertension1 (0.83--1.2)0.960Diabetes Mellitus1 (0.89--1.13)0.986Dyslipidemia0.92 (0.68--1.24)0.577Coronary Artery Disease0.98 (0.82--1.16)0.805Prior PCI1.05 (0.84--1.31)0.670Prior Open Heart Surgery1.15 (1.09--1.21)\<0.001Dialysis0.95 (0.64--1.41)0.797COPD0.94 (0.75--1.17)0.558Peripheral Vascular Disease1.01 (0.81--1.25)0.948Permanent Pacemaker1.1 (0.74--1.62)0.644Stroke0.81 (0.58--1.13)0.215Pre-Procedural Ejection Fraction (1ss0%)1.05 (1.03--1.07)\<0.001Pre-Procedural Mean Pressure Gradient1 (1--1.01)\<0.001Procedure Time (10 min)0.98 (0.96--0.99)0.001Access Site TransfemoralReferent Direct Aortic0.76 (0.67--0.85)\<0.001 Subclavian or Suprasternal2.42 (1.4--4.2)0.002 Transapical0.49 (0.41--0.58)\<0.001Anesthesia Type General AnesthesiaReferent Local/Conscious Sedation1.19 (1.06--1.35)0.004Valve Used Medtronic CoreValve or Evolut-RReferent Edwards XT or S30.99 (0.96--1.03)0.647 Portico0.43 (0.25--0.73)0.002Valve in Valve Procedure1.28 (1.15--1.41)\<0.001Procedure prior to Weekend^a^0.88 (0.77--1.01)0.061Hazard ratios above 1 indicate shorter time to discharge and shorter length of stay, whereas the opposite is true for ratios below 1. *STS* Society of Thoracic Surgeons adult cardiac surgery risk score, *NYHA* New York Heart Association functional classification, *COPD* chronic obstructive pulmonary disease, *PCI* percutaneous coronary intervention^a^Refers to procedures that take place one day prior to the weekend

Patients were discharged sooner if they were NYHA class 1 or 2 (HR = 1.28, 95% CI 1.10--1.49, *p* = 0.001) or NYHA class 3 (HR =1.16, 95% CI 1.03--1.31, *p* = 0.019) compared to NYHA class 4. Every 10% increase in ejection fraction was associated with shorter length of stay (HR = 1.05, 95% CI 1.03--1.07, *p* \< 0.001), as was each one mmHg increase in the pre-procedural mean aortic valve pressure gradient (HR = 1.004, 95% CI 1.002--1.01, *p* \< 0.001). Patients who had at least one prior open heart surgery were also discharged sooner (HR = 1.15, 95%CI 1.09--1.21, *p* \< 0.001).

Procedure factors had important impact on post-TAVR LOS. Patients receiving conscious sedation, rather than general anesthesia, had a significantly shorter LOS (HR = 1.19, 95% CI 1.06--1.35, *p* = 0.004). Compared to patients receiving TAVR via trans-femoral approach, direct aortic approach was associated with longer LOS (HR = 0.76, 95% CI 0.67--0.85, *p* \< 0.001), as was trans-apical approach (HR = 0.49, 95% CI 0.41--0.58, *p* \< 0.001). A subclavian or suprasternal approach was associated with earlier discharge compared to transfemoral (HR = 2.42, 95% CI 1.40--4.20, *p* = 0.002); however, there were few patients with these alternative access sites (*n* = 3) in our cohort. Longer TAVR procedure duration was associated with longer LOS (HR = 0.98 for every 10 min increase, 95% CI 0.96--0.99, *p* = 0.001). In terms of valve type, implantation of a Portico trans-catheter heart valve was associated with longer LOS (HR = 0.43, 95% CI 0.25--0.73, *p* \< 0.001). A valve in valve procedure was associated with shorter LOS (HR = 1.28, 95% CI 1.15--1.41, *p* \< 0.001).

The unadjusted HR suggest that almost all post procedure complications are statistically associated with longer LOS, except for new arrhythmia and myocardial infarction (*p* = 0.090, *p* = 0.055, respectively). When adjusted for baseline characteristics, all post-procedural complications were associated with a statistically significant increase in length of stay (Table [3](#Tab3){ref-type="table"}).Table 3Relationship between Presence of Complication to Post-TAVR Length of Stay, with Unadjusted and Adjusted Analyses. Hazard ratios with 95% confidence intervals for post-TAVR LOS according to presence of different complications. Includes unadjusted analysis as well as multivariable adjustment for baseline and procedural characteristicsUnadjusted Hazard Ratio*p* ValueAdjusted Hazard Ratio*p* ValueVascular Major0.46 (0.33--0.64)\<0.0010.42 (0.37--0.49)\<0.001 Minor0.79 (0.64--0.97)0.0230.73 (0.58--0.93)0.011Stroke0.31 (0.19--0.50)\<0.0010.35 (0.22--0.55)\<0.001MI0.33 (0.11--1.02)0.0550.6 (0.42--0.84)0.003Arrhythmia0.88 (0.76--1.02)0.0900.75 (0.61--0.93)0.008Permanent Pacemaker0.59 (0.48--0.73)\<0.0010.49 (0.37--0.64)\<0.001Bleeding Life Threatening0.30 (0.17--0.55)\<0.0010.28 (0.17--0.46)\<0.001 Major0.54 (0.38--0.76)\<0.0010.56 (0.46--0.68)\<0.001 Minor0.69 (0.49--0.98)0.0360.82 (0.7--0.95)0.009Transfusion0.56 (0.46--0.68)\<0.0010.59 (0.54--0.65)\<0.001Cardio-pulmonary bypass0.32 (0.12--0.87)0.0250.27 (0.18--0.41)\<0.001Emergency operation0.31 (0.15--0.65)0.0020.31 (0.11--0.91)0.033Open heart surgery0.29 (0.09--0.89)0.0300.27 (0.18--0.41)\<0.001Any Major Complication^a^0.44 (0.37--0.52)\<0.0010.38 (0.28--0.5)\<0.001Hazard ratios \>1 indicate shorter time to discharge, while hazard ratios \<1 indicate prolonged time to discharge. *MI* myocardial infarction^a^Patient with any of the following complications: major vascular, stroke, MI, new permanent pacemaker, life-threatening bleeding, major bleeding, cardio-pulmonary bypass, emergency operation, or open heart surgery

Discussion {#Sec8}
==========

In this multi-center study of contemporary TAVR procedures, we found a wide variation in post-TAVR LOS. We identified a number of potentially modifiable factors that influenced LOS, such as access route, type of anesthesia, the timing of the procedure prior to the weekend, procedure time, and valve type. These are potential targets for quality improvement initiatives. Importantly, we found that post-procedural complications were strongly associated with prolonged stay.

Improving efficiency of health care delivery is of particular importance in the current era of budgetary constraints such that scarce health care resources are used optimally. One target for improving efficiency is reduction of LOS. Indeed, there is an abundant literature on LOS in different areas of medicine, specifically the drivers of prolonged LOS as well as strategies to improve it. For example, malnutrition measured by recent weight loss or a BMI below 20 has been associated with prolonged LOS \[[@CR21]\]. Surgical site infections are a major driver of LOS in the surgical literature with a doubling of the LOS \[[@CR22]\]. Early interventions and internal fixations have been associated with reduced LOS in patients with hip fractures \[[@CR23]\]. Improving patients' renal function \[[@CR24]\] as well as pulmonary function have been associated with shorter LOS in patients undergoing cardiac surgery \[[@CR25]\]. Increasing hospital volume has been associated with a reduced LOS \[[@CR26]\]. Many of these factors are potentially modifiable and thus targets for quality improvement.

TAVR is an example of a complex intervention, targeted to an elderly patient population, often with multiple co-morbidities. Moreover, it is extremely resource intensive, and in many jurisdictions, limited to select tertiary hospitals, each with limited funding. These supply factors, combined with an exponentially growing demand, in particular as indications expand beyond only inoperable and very high risk patients, make TAVR an especially relevant area to identify potential targets for improving efficiency. The limited data on TAVR LOS currently suggests that there is variation in LOS \[[@CR13], [@CR27], [@CR28]\].

In our study, we confirmed this wide variation in LOS, extending from 2 days to 59 days. We were able to identify a number of baseline patient characteristics that were associated with prolonged LOS, including prior atrial fibrillation, age, and lower baseline ejection fraction. Indeed, LOS appears to be a surrogate for the burden of co-morbidity. Although these factors are non-modifiable, they nonetheless should alert health care providers of the potential for a longer LOS, and as such, pre-emptive measures could be put into place early to facilitate transitions to the community or in-patient rehabilitation.

We also identified a number of potentially modifiable procedural factors such as procedure done before the weekend, valve type and conscious sedation. Indeed, other groups are evaluating the use of conscious sedation in combination with a care pathway to facilitate next day discharge post TAVR \[[@CR29]--[@CR31]\]. Conscious Sedation and non- surgical access have been associated with less delirium and might explain the shorter LOS. \[[@CR32]\] The relationship between length of procedure and higher NYHA with LOS might be explained by the increased incidence of complications in sicker patients. Similarly, in hospital TAVI patients are more frail and await rehabilitation and hence have longer LOS. \[[@CR33]\] The relationship between Portico valve and LOS might be attributed to a learning curve since it is a newer valve compared to Corevalve and Sapien valves. Longer LOS when the TAVR procedure is performed prior to the weekend has face validity and may be related to delays in obtaining post-procedural echocardiograms during the weekend, or being able to put into place the necessary transition supports such as homecare. If so, this suggests that development of strategies to mitigate these delays; one such strategy could be performing echocardiography immediately post procedure. These are all potential areas for future study.

It is important to note the complex relationship between pre-procedural LOS and post-procedural hospitalization duration. We grouped patients admitted to hospital 0--2 days pre-TAVR as they likely received an elective TAVR. It is clear that elective pre-admission did not impact post-TAVR LOS. In contrast, patients who were admitted for longer periods prior to their TAVR likely represent patients who had decompensated heart failure. This group has a substantially longer LOS; this illustrates that once TAVR patients deteriorate while waiting for their procedure, this translates into a slower recovery post-procedure. This reinforces the importance of diligent wait-time management for TAVR patients.

In addition, there are some general measures that have been shown to help reduce LOS which might also be relevant to TAVR patients. Patients with expected long LOS might benefit from preemptive interventions \[[@CR34], [@CR35]\] including geriatric care and pre-procedural rehab \[[@CR36], [@CR37]\], nutrition supplementation \[[@CR38]\], reducing bleeding risk \[[@CR39]\], optimize periprocedural practice \[[@CR29], [@CR40], [@CR41]\], and post procedural rehabilitation \[[@CR42]\].

Our study provides a number of new insights to the literature. First, we used competing risk models to include all TAVR patients in our analyses, not only those who survived to discharge. This eliminates the potential biases introduced by only studying patients selected for survival. In addition, we have shown that in TAVR the occurrence of a post-procedural complication has a remarkable influence on LOS and one can hypothesize that the occurrence of complications may be one of the causal pathways by which the factors identified in our models impact LOS. The extended LOS likely explains in part the increased costs associated with complications \[[@CR8], [@CR39]\].

Our study must be interpreted in the context of several limitations that merit discussion. Although we had a relatively larger sample size across two countries, and used a clustered model to account for potential site related factors, our cohort was limited to three tertiary care hospitals that had wide variability in clinical practice (access site, sedation type, etc.), which impacts the generalizability of our findings. Second, although we identified factors associated with LOS, it does not follow necessarily that changing those factors will translate to shorter LOS. Instead, potential strategies impacting those factors must be empirically tested. Third, we did not have data on frailty or social status. The number of portico cases was small as were subclavian and direct aortic access routes and therefore, any conclusions regarding these variables may be explained by the learning curve. Finally, our study was an observational study, and there may have residual confounders that we did not account for. As such, our results should be considered hypothesis generating and not conclusive.

Conclusions {#Sec9}
===========

In conclusion, this multicenter study identified a number of important modifiable patient and procedural factors associated with LOS. Future studies should evaluate if interventions focused on these potentially modifiable factors will translate to shorter LOS.
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